-
Nivolumab, sold
under the
brand name Opdivo, is an anti-cancer
medication used to
treat a
number of
types of cancer. This
includes melanoma, lung cancer...
-
Nivolumab/relatlimab, sold
under the
brand name Opdualag, is a fixed-dose
combination medication use to
treat melanoma. It
contains nivolumab, a programmed...
- (EU), for
second line
treatment of
metastatic melanoma in
November 2012.
Nivolumab, in
combination with
ipilimumab is
indicated for the
treatment of intermediate...
- molecules, and the
first clinical trial was
launched in 2006,
evaluating nivolumab. As of 2017, more than 500
clinical trials involving PD-1 and PD-L1 inhibitors...
-
designed for the
treatment of melanoma. It is used in
combination with
nivolumab to
treat melanoma.
Relatlimab is a
Lymphocyte activation gene-3 (LAG-3)...
-
Approved checkpoint inhibitors include antibodies such as ipilimumab,
nivolumab, and pembrolizumab.
Dendritic cell
therapy provokes anti-tumor responses...
- the
combination of
CIMAvax with the PD-1
inhibitor checkpoint inhibitor nivolumab was safe and well
tolerated in 13
people with
advanced non-small cell...
-
antibody nivolumab (under the
brand name
Opdivo and
developed by Bristol-Myers Squibb) were
published in 2010. It was
approved in 2014.
Nivolumab is approved...
- the
immune system.
Atezolizumab is an anti PD-L1
monoclonal antibody.
Nivolumab and
Pembrolizumab are anti PD-1
monoclonal antibodies.
Ipilimumab is a...
- the
company received FDA
approval for the use of the PD-1
inhibitor nivolumab (Opdivo) in
treating patients whose skin
cancer cannot be
removed or have...
